{"id":"W4296613459","doi":"10.1016/s2152-2650(22)00982-x","title":"Poster: MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis-JAK Inhibitor-Naïve or With Suboptimal Response to Ruxolitinib-Preliminary Data From the MANIFEST Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Myeloproliferative neoplasm; Internal medicine; Oncology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006499308,0.0006172915,0.0009703966,0.0001978798,0.0002563281,0.0005882196,0.0003377414,0.0004411125,0.005435879],"category_scores_gemma":[0.0007529628,0.000192919,0.0008244182,0.0001725044,0.0001947556,0.0004281954,0.0002025881,0.001426275,0.0008410929],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005206733,"about_ca_system_score_gemma":0.0005061769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000762803,"about_ca_topic_score_gemma":0.003019768,"domain_scores_codex":[0.9998367,0.0000597008,0.00001648548,0.00002792522,0.00002076544,0.00003853625],"domain_scores_gemma":[0.9997111,0.0000850104,0.00004491386,0.00001560502,0.00002017601,0.0001231898],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4598752,0.01322534,0.03557542,0.001402956,0.002879299,0.00124457,0.0002142454,0.002133369,0.02900626,0.0003794699,0.03315942,0.4209045],"study_design_scores_gemma":[0.2992041,0.27808,0.3493231,0.00039598,0.006249614,0.003181126,0.0002683874,0.003774429,0.01146609,0.0007917165,0.04713241,0.000133059],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9617941,0.02076706,0.0004932363,0.00380617,0.0009826242,0.0004419733,0.002043977,0.0001559364,0.009514929],"genre_scores_gemma":[0.9861389,0.005054006,0.0006417903,0.001493472,0.0006520294,0.0001419263,0.002097947,0.00001858627,0.003761256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005435879,"threshold_uncertainty_score":0.01818484,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03944203951438547,"score_gpt":0.311241012791081,"score_spread":0.2717989732766955,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}